|
C41 Analogs
This invention relates generally to neurodegenerative diseases and conditions, such as Alzheimer’s Disease, characterized with dysfunctional energetic function, unregulated microglia phagocytic activity and other related de-regulated biological functions. This invention further relates to methods and compositions for treating such neurodegenerative...
Published: 9/24/2024
|
Inventor(s): Wei Wang, Rui Chang, Vijayan Ramachandran, Patrick Ronaldson
Keywords(s):
Category(s): Technology Classifications > Healthcare Portfolios > Neurology, Technology Classifications > Life Sciences > Nutraceuticals, Technology Classifications > Life Sciences > Small Molecules, Technology Classifications > Life Sciences > Therapeutics, Technology Classifications > Life Sciences > Biologics
|
|
A Novel Chemical Entity, Mary1, for the Treatment Mitochondrial Dysfunction, Vascular Injury, Kidney Diseases, and Organ Aging
This invention is a novel compound that can be used as a treatment for Acute Kidney Injury (AKI). This new method utilizes a small molecule agonist, capable of increasing mitochondrial biogenesis, which helps restore mitochondrial homeostasis and improves renal function and recovery. The compound showed beneficial effect in mouse model experiments.
Background:...
Published: 8/5/2024
|
Inventor(s): Rick Schnellmann, Paul Victor Santiago Raj
Keywords(s):
Category(s): Technology Classifications > Healthcare Portfolios > Nephrology/Renal, Technology Classifications > Life Sciences > Small Molecules
|
|
Discovery of Novel Wnt Inhibitors and Uses Thereof
Canonical WNT (Wingless/integrase 1) signaling is an important developmental pathway that has attracted increased attention for anti-cancer drug discovery. Researchers at the University of Arizona are investigating utility for the compounds herein for the treatment of colorectal cancer as well as potential disease modifying agents for the treatment...
Published: 11/14/2024
|
Inventor(s): Christopher Hulme, Sammantha Rokey, Yeng Jeng Shaw, Curtis Thorne, Timothy Chavez, Carly Cabel, Nathan Bedard, Sourav Banerjee
Keywords(s):
Category(s): Technology Classifications > Life Sciences > Therapeutics, Technology Classifications > Life Sciences > Small Molecules, Technology Classifications > Healthcare Portfolios
|
|
CC16-Derived Analogs for the Treatment of Inflammatory and Obstructive Lung Diseases
This innovation relates to analogs/mimetics of CC16 also known as Urinary protein 1 (UPI), or Clara cell protein, or club cell protein. This protein is targeted for the treatment of cancer, chronic obstructive pulmonary disease, asthma, cystic fibrosis and any other diseases that CC16 may have activity in. The inventors have discovered a novel site...
Published: 6/10/2024
|
Inventor(s): Julie Ledford, Josef Vagner, Stefano Guerra, Michael Johnson
Keywords(s):
Category(s): Technology Classifications > Life Sciences > Biologics, Technology Classifications > Life Sciences > Small Molecules, Technology Classifications > Life Sciences > Therapeutics, Technology Classifications > Healthcare Portfolios > Respiratory & Pulmonary
|
|
Compositions for Treating and Preventing Lung Disease
This invention is a novel pharmaceutical composition for supplemental expression of a protein for the treatment of asthma and other pulmonary diseases. This method utilizes a surfactant protein, delivered via aerosolization to offer a more effective treatment option.
Background:
Asthma medicines of the 1940’s and 1950’s consisted of epinephrine...
Published: 11/20/2024
|
Inventor(s): Julie Ledford, Monica Kraft, Josef Vagner
Keywords(s):
Category(s): Technology Classifications > Healthcare Portfolios > Respiratory & Pulmonary, Technology Classifications > Life Sciences > Small Molecules, Technology Classifications > Life Sciences > Therapeutics
|
|
Coronavirus Therapeutics
This technology introduces a potent covalent enzyme inhibitor designed specifically for targeting the cysteine protease, PLpro, a key player in the replication process of SARS coronaviruses like SARS-CoV-2 and MERS. Unlike traditional small molecule inhibitors, this inhibitor offers unparalleled efficacy and specificity, making it a promising candidate...
Published: 6/5/2024
|
Inventor(s): Rui Xiong, Gregory Thatcher, Divakar Indukuri, Kiira Ratia, Li jun Rong
Keywords(s):
Category(s): Technology Classifications > Healthcare Portfolios > Infectious Diseases, Technology Classifications > Healthcare Portfolios > Respiratory & Pulmonary, Technology Classifications > Life Sciences > Small Molecules, Technology Classifications > Life Sciences > Therapeutics
|
|
Broad Applications of PROTACS for Targeted Protein Degradation Employing a Molecular Glue-Linker-Warhead Approach
This technology is a high-affinity E3-ligase binder, which has been optimized toward the specific proteolysis targeting chimera (PROTAC) mediated degradation of particular proteins. A PROTAC is a heterobifunctional molecule composed of two active domains and a linker, capable of removing specific unwanted proteins. This technology opens the door for...
Published: 2/6/2024
|
Inventor(s): Christopher Hulme, Kevin Schofield
Keywords(s):
Category(s): Technology Classifications > Life Sciences > Small Molecules, Technology Classifications > Life Sciences > Therapeutics
|
|
Bioorthogonal Activation of PROTAC Prodrugs
Utilizing proteolysis targeting chimeras (PROTACs) to degrade proteins that are important for tumorigenesis has become a potential therapeutic strategy for cancer. This innovation is an on-demand prodrug strategy called click-release proteolysis targeting chimeras, or “crPROTACs.” The crPROTACs strategy utilizes bioorthogonal chemistry and...
Published: 1/16/2024
|
Inventor(s): Wei Wang, Mengyang Chang, Giri Gnawali
Keywords(s):
Category(s): Technology Classifications > Healthcare Portfolios > Oncology, Technology Classifications > Life Sciences > Therapeutics, Technology Classifications > Life Sciences > Small Molecules
|
|
HCV3 for Multiple Indications involving Alpha2B Receptor Modulation
The invention is a preclinical drug candidate (HCV3) based on the discovery that substituted 1-arylalkyl-4-acylaminopiperide compounds have shown to be effective antagonists of mu-, delta-, and kappa-opioid receptors and/or alpha-2-adrenoreceptors. HCV3 can be used to treat clinical conditions that are due to activation of any one or more of the receptors,...
Published: 3/12/2024
|
Inventor(s): Victor Hruby, Ruben Vardanyan
Keywords(s):
Category(s): Technology Classifications > Life Sciences > Small Molecules, Technology Classifications > Life Sciences > Therapeutics
|
|
Redox-Activated Pro-Chelators
Novel molecular design extends the reach of iron chelators to applications in cancer chemotherapy. This invention not only recognizes the higher demand of iron that characterizes cancer cells, but also takes into account other physiological differences between malignant cells and the surrounding tissue. Specifically, pro-drugs are designed to activate...
Published: 3/12/2024
|
Inventor(s): Elisa Tomat, Eman Akam, Yu-Shien Sung
Keywords(s):
Category(s): Technology Classifications > Life Sciences > Small Molecules, Technology Classifications > Life Sciences > Therapeutics, Technology Classifications > Healthcare Portfolios > Blood & Lymphatic Disease, Technology Classifications > Healthcare Portfolios > Oncology
|
